HOUSTON, Feb. 3, 2010 (GLOBE NEWSWIRE) -- Power3 Medical Products, Inc. (OTCBB:PWRM) announced that 4 abstracts covering results from clinical validation trials of the NuroPro® AD test for Alzheimer’s disease were submitted to the 2010 annual meeting of the International Congress of Alzheimer’s Disease, taking place July 2010. The NuroPro AD test was developed to help clinicians distinguish patients with Alzheimer’s disease from “normal” individuals and patients with other neurological disorders. The test, developed by Power3, is a panel of 57 blood serum protein biomarkers evaluated by biostatistical analysis to predict the probability a patient has Alzheimer’s disease. The test is intended to solve the critical challenge facing physicians, clinicians, and patients for quick, early stage, and accurate diagnosis of this debilitating disease as well as to provide guidance for therapy, and monitor treatment response.
